The potential of the transformer-based survival analysis model, SurvTrace, for predicting recurrent cardiovascular events and stratifying high-risk patients with ischemic heart disease.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 31 10 2023
accepted: 12 05 2024
medline: 18 6 2024
pubmed: 18 6 2024
entrez: 18 6 2024
Statut: epublish

Résumé

Ischemic heart disease is a leading cause of death worldwide, and its importance is increasing with the aging population. The aim of this study was to evaluate the accuracy of SurvTrace, a survival analysis model using the Transformer-a state-of-the-art deep learning method-for predicting recurrent cardiovascular events and stratifying high-risk patients. The model's performance was compared to that of a conventional scoring system utilizing real-world data from cardiovascular patients. This study consecutively enrolled patients who underwent percutaneous coronary intervention (PCI) at the Department of Cardiovascular Medicine, University of Tokyo Hospital, between 2005 and 2019. Each patient's initial PCI at our hospital was designated as the index procedure, and a composite of major adverse cardiovascular events (MACE) was monitored for up to two years post-index event. Data regarding patient background, clinical presentation, medical history, medications, and perioperative complications were collected to predict MACE. The performance of two models-a conventional scoring system proposed by Wilson et al. and the Transformer-based model SurvTrace-was evaluated using Harrell's c-index, Kaplan-Meier curves, and log-rank tests. A total of 3938 cases were included in the study, with 394 used as the test dataset and the remaining 3544 used for model training. SurvTrace exhibited a mean c-index of 0.72 (95% confidence intervals (CI): 0.69-0.76), which indicated higher prognostic accuracy compared with the conventional scoring system's 0.64 (95% CI: 0.64-0.64). Moreover, SurvTrace demonstrated superior risk stratification ability, effectively distinguishing between the high-risk group and other risk categories in terms of event occurrence. In contrast, the conventional system only showed a significant difference between the low-risk and high-risk groups. This study based on real-world cardiovascular patient data underscores the potential of the Transformer-based survival analysis model, SurvTrace, for predicting recurrent cardiovascular events and stratifying high-risk patients.

Identifiants

pubmed: 38889124
doi: 10.1371/journal.pone.0304423
pii: PONE-D-23-35647
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0304423

Informations de copyright

Copyright: © 2024 Shinohara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Hiroki Shinohara (H)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Satoshi Kodera (S)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Yugo Nagae (Y)

Department of Planning, Information and Management, University of Tokyo, Tokyo, Japan.

Takashi Hiruma (T)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Atsushi Kobayashi (A)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Masataka Sato (M)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Shinnosuke Sawano (S)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Tatsuya Kamon (T)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Koichi Narita (K)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Kazutoshi Hirose (K)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Hiroyuki Kiriyama (H)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Akihito Saito (A)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Mizuki Miura (M)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Shun Minatsuki (S)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Hironobu Kikuchi (H)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Norifumi Takeda (N)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Hiroshi Akazawa (H)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Hiroyuki Morita (H)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.

Issei Komuro (I)

Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan.
International University of Health and Welfare, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH